تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
16.79 US$
−0.23 US$ · -1.35%
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
عند الإغلاق
16.79 US$
−0.23 US$ · -1.35%
بعد ساعات التداول
16.79 US$
0.00 US$ · 0.00%
12 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 16.79 US$
نطاق 52 أسبوعًا
السعر الحالي 16.79 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
55
قيمة عادلة
المشاعر
66
صعودي
المخاطر
40
مخاطر متوسطة
الزخم
57
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 16.79 US$
نطاق 52 أسبوعًا
السعر الحالي 16.79 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 858 ألف USD | 636 ألف USD | — | — | — |
| تكلفة البضاعة المباعة | 92 ألف USD | 39.51 مليون USD | 150 ألف USD | — | 109 ألف USD |
| الربح الإجمالي | 766 ألف USD | −38.87 مليون USD | −150 ألف USD | — | −109 ألف USD |
| البحث والتطوير | 19.6 مليون USD | 41.51 مليون USD | 53.54 مليون USD | 40.69 مليون USD | 26.91 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 14.33 مليون USD | 18.33 مليون USD | 25.39 مليون USD | 27.2 مليون USD | 18.74 مليون USD |
| نفقات التشغيل | 28.83 مليون USD | 21.63 مليون USD | 78.93 مليون USD | 67.88 مليون USD | 45.65 مليون USD |
| دخل الفوائد | 2.19 مليون USD | 4.22 مليون USD | 6.15 مليون USD | 1.96 مليون USD | 54 ألف USD |
| مصاريف الفوائد | — | — | — | — | 10 ألف USD |
| الاستهلاك والإطفاء | 92 ألف USD | 131 ألف USD | 150 ألف USD | 167 ألف USD | 109 ألف USD |
| الدخل التشغيلي | −28.06 مليون USD | −60.5 مليون USD | −78.93 مليون USD | −67.88 مليون USD | −45.65 مليون USD |
| صافي الدخل | −8.98 مليون USD | −57.78 مليون USD | −74.56 مليون USD | −66.65 مليون USD | −47.01 مليون USD |
تم تحديث حقائق الشركة 13 أكتوبر 2026.
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI2.26 مليون0.00%2.3 ترليون USD0.03%381.57 US$-0.10%
Vanguard Extended Market ETFVXF544.79 ألف0.00%95.4 مليار USD0.05%233.52 US$-0.63%
iShares Micro-Cap ETFIWC204.22 ألف0.02%1.32 مليار USD0.60%181.66 US$-0.73%
Dimensional - US Small Cap ETFDFAS113.61 ألف0.00%33.87 مليار USD0.31%78.17 US$-0.23%
U.S. Micro Cap Portfolio ETFDFMC100.26 ألف0.00%7.56 مليار USD0.43%57.70 US$-0.20%
Avantis U.S. Small Cap Equity ETFAVSC26.59 ألف—3.08 مليار USD0.25%69.97 US$-0.01%
U.S. Vector Equity Portfolio ETF Class SharesDXUV12.24 ألف0.00%6.18 مليار USD0.26%68.32 US$+0.06%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR11.64 ألف0.00%45.59 مليار USD0.17%84.43 US$-0.01%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
